替比夫定治疗慢性乙型肝炎过程中患者血清IL-22的变化及意义

目的：观察替比夫定治疗前后慢性乙型肝炎患者血清中白细胞介素22（IL-22）水平的变化。方法：84例慢性乙型肝炎患者接受替比夫定抗病毒治疗,采用酶联免疫吸附法检测治疗前及治疗后IL-22血清浓度变化,并同时检测肝功能ALT、HBV-DNA含量变化。此外选择30例健康人群作为对照组。结果：慢性乙型肝炎患者血清中IL-22水平较健康对照组明显升高,差异有统计学意义（P〈0.01）;替比夫定抗病毒治疗后较治疗前血清中IL-22、ALT及HBV-DNA水平均下降,差异有统计学意义（P〈0.05）。结论：替比夫定能够通过抑制HBV复制并改善患者细胞免疫功能,降低慢性乙型肝炎患者血清中IL-22的水平。

Changes in Serum IL-22 and Their Significance in Chronic Hepatitis B Patients Treated with Telbivudine

Objective： To observe the changes in serum interleukin 22（ IL-22） level of the patients with chronic hepatitis B（ CHB） before and after telbivudine treatment. Methods： 84 cases of CHB were treated with telbivudine,with the serum IL-22 level measured by enzyme-linked immununosorbent assay（ ELISA） and with the hepatic function tested as well before and after the treatment. 30 healthy individuals were taken as the control group. Results： Compared with that in the control group,the level of serum IL-22 rose significantly in CHB patients（ P 0. 01）; compared with those before the treatment,the levels of serum IL-22,HBV-DNA and ALT dropped in CHB patients after the treatment with telbivudine（ P 0. 05）. Conclusion： Telbivudine can lower the serum IL-22 level in CHB patients through inhibiting HBV reproduction and improving cellular immunity function in CHB patients.